Piloting a clinical laboratory method to evaluate the influence of potential modified risk tobacco products on smokers' quit-related motivation, choice, and behavior

Ozga-Hess, Jenny E.; Felicione, Nicholas J.; Ferguson, Stuart G.; Dino, Geri; Elswick, Daniel; Whitworth, Catherine; Turiano, Nicholas A.; Blank, Melissa D.

doi:10.1016/j.addbeh.2019.106105

Cited by 9 publications

(3 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, mHealth has been used to support smoking cessation 7 , 8 increase HIV anti-retroviral therapy adherence among patients with comorbid substance use disorders 9 , 10 , and improve Hepatitis C testing and health outcomes among patients with an opioid use disorder 11 . mHealth has also utilized ecological momentary assessment methods to identify associations between mood, environment, drug cravings, and risk behaviors for various populations of tobacco users, 12 , 13 methadone maintainance patients, 14 , 15 and PWID 3 , 16 – 18 . These and other studies 19 demonstrate mHealth's potential for conducting health-related research among people who use drugs (see review by Carpenter et al.)…”

Section: Introductionmentioning

confidence: 99%

Mobile Phone and Internet use among People who Inject Drugs: Implications for Mobile Health Interventions

et al. 2022

View full text Add to dashboard Cite

Background: Mobile health (mHealth) interventions have the potential to improve substance use treatment engagement and outcomes, and to reduce risk behaviors among people who inject drugs (PWID). However, there are few studies assessing mobile technology use among PWID and none have investigated continuity of mobile phone use. Methods: We surveyed 494 PWID. We used bivariate (independent-sample t- and chi-square tests) and multivariate (logistic regression) analyses to determine whether mobile phone and/or internet use differed as a function of participant- and/or injection-related characteristics. Results: Most participants (77%) had a mobile phone, with 67% having a phone that was free of charge. Participants with a phone were significantly less likely to be homeless (AOR = 0.28), to have shared syringes (AOR = 0.53), and to have reused syringes (AOR = 0.26) in the past 3 months. We observed high rates of phone and number turnover, with more than half reporting that they got a new phone (57%) and/or number (56%) at least once within the past 3 months. Most participants were familiar with using the internet (80% ever use), though participants who had ever used the internet were younger (AOR = 0.89), were less likely to be homeless (AOR = 0.38), were less likely to have shared syringes (AOR = 0.49), and were more likely to have injected methamphetamine by itself (AOR = 2.49) in the past 3 months. Conclusions: Overall, mobile technology and internet use was high among our sample of PWID. Several factors should be considered in recruiting diverse samples of PWID to minimize bias in mHealth study outcomes, including mobile phone access and protocol type (text- vs internet-based).

show abstract

Section: Introductionmentioning

confidence: 99%

Mobile Phone and Internet use among People who Inject Drugs: Implications for Mobile Health Interventions

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Two studies reported the number of participants excluded as a result of a low CO reading. 5,6 The Russell standard sought to standardise the measurement and reporting of smoking status in trials with a CO reading of 10 ppm or more signifying smoking. 3 Carbon monoxide typically has a half-life of around 4 h, meaning someone with a level of 12 ppm would be expected to have a level of 6 ppm 4 h later if they did not smoke during that period.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biochemical Verification of Tobacco-Use as an Inclusion Criterion in Smoking Cessation Trials- Lessons From the Cessation of Smoking Trial in the Emergency Department

et al. 2023

View full text Add to dashboard Cite

INTRODUCTION Biochemical verification of smoking status prior to recruitment into smoking cessation trials is widely used to confirm smoking status, most commonly using exhaled carbon monoxide (CO). There is variation in the level of CO used as a biochemical inclusion criterion, and thus the possibility for people reporting to be current smokers to be incorrectly excluded from trials. METHODS As part of the Cessation of Smoking Trial in the Emergency Department, people attending the Emergency Department (ED) who reported being current daily smokers underwent CO testing to confirm eligibility. Elective semi-structured interviews were undertaken with the researchers who recruited participants. As part of the interviews, researchers were asked their views and experiences with CO testing. RESULTS Of the 1320 participants who reported being current daily smokers and underwent CO testing, 300 (22.7%) blew a CO reading of 7 ppm or less and were excluded from taking part. Possible explanations offered by researchers for participants blowing low CO readings were (1) long wait times in the ED, therefore a long period having elapsed since people had last smoked and (2) patients having reduced smoking for the period before the ED attendance due to ill health. CONCLUSIONS Biochemical verification has the potential to improve internal validity of smoking cessation for inclusion in trials, but at the cost of reduced generalisability through exclusion of participants who would receive the intervention if it were implemented in practice. We would recommend researchers carefully consider whether it is appropriate and necessary to include biochemical verification as an inclusion criterion.

show abstract

Electronic cigarettes for smoking cessation

Hartmann‐Boyce

McRobbie

Butler

et al. 2021

Cochrane Database of Systematic Reviews

154

102

View full text Add to dashboard Cite

BackgroundElectronic cigarettes (ECs) are electronic devices that heat a liquid into an aerosol for inhalation. The liquid usually comprises propylene glycol and glycerol, with or without nicotine and flavours, and stored in disposable or refillable cartridges or a reservoir. Since ECs appeared on the market in 2006 there has been a steady growth in sales. Smokers report using ECs to reduce risks of smoking, but some healthcare organizations, tobacco control advocacy groups and policy makers have been reluctant to encourage smokers to switch to ECs, citing lack of evidence of efficacy and safety. Smokers, healthcare providers and regulators are interested to know if these devices can help smokers quit and if they are safe to use for this purpose. This review is an update of a review first published in 2014. ObjectivesTo evaluate the safety and effect of using ECs to help people who smoke achieve long-term smoking abstinence. Search methodsWe searched the Cochrane Tobacco Addiction Group's Specialized Register, the Cochrane Central Register of Controlled Trials (CEN-TRAL), MEDLINE, Embase, and PsycINFO for relevant records from 2004 to January 2016, together with reference checking and contact with study authors. Selection criteriaWe included randomized controlled trials (RCTs) in which current smokers (motivated or unmotivated to quit) were randomized to EC or a control condition, and which measured abstinence rates at six months or longer. As the field of EC research is new, we also included cohort follow-up studies with at least six months follow-up. We included randomized cross-over trials, RCTs and cohort follow-up studies that included at least one week of EC use for assessment of adverse events (AEs). Data collection and analysisWe followed standard Cochrane methods for screening and data extraction. Our main outcome measure was abstinence from smoking after at least six months follow-up, and we used the most rigorous definition available (continuous, biochemically validated, longest follow-up). We used a fixed-effect Mantel-Haenszel model to calculate the risk ratio (RR) with a 95% confidence interval (CI) for each study, and where appropriate we pooled data from these studies in meta-analyses.

show abstract

Piloting a clinical laboratory method to evaluate the influence of potential modified risk tobacco products on smokers' quit-related motivation, choice, and behavior

Cited by 9 publications

References 53 publications

Mobile Phone and Internet use among People who Inject Drugs: Implications for Mobile Health Interventions

Mobile Phone and Internet use among People who Inject Drugs: Implications for Mobile Health Interventions

Biochemical Verification of Tobacco-Use as an Inclusion Criterion in Smoking Cessation Trials- Lessons From the Cessation of Smoking Trial in the Emergency Department

Electronic cigarettes for smoking cessation

Contact Info

Product

Resources

About